AR022510A1 - Formulaciones de vacunas contra el papilomavirus humano - Google Patents

Formulaciones de vacunas contra el papilomavirus humano

Info

Publication number
AR022510A1
AR022510A1 ARP000100495A ARP000100495A AR022510A1 AR 022510 A1 AR022510 A1 AR 022510A1 AR P000100495 A ARP000100495 A AR P000100495A AR P000100495 A ARP000100495 A AR P000100495A AR 022510 A1 AR022510 A1 AR 022510A1
Authority
AR
Argentina
Prior art keywords
formulations
against human
vaccines against
salt
human papilomavirus
Prior art date
Application number
ARP000100495A
Other languages
English (en)
Spanish (es)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR022510A1 publication Critical patent/AR022510A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ARP000100495A 1999-02-05 2000-02-04 Formulaciones de vacunas contra el papilomavirus humano AR022510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11872399P 1999-02-05 1999-02-05

Publications (1)

Publication Number Publication Date
AR022510A1 true AR022510A1 (es) 2002-09-04

Family

ID=22380362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100495A AR022510A1 (es) 1999-02-05 2000-02-04 Formulaciones de vacunas contra el papilomavirus humano

Country Status (15)

Country Link
US (1) US6251678B1 (https=)
EP (1) EP1150712B1 (https=)
JP (2) JP4841726B2 (https=)
KR (1) KR20010093290A (https=)
AR (1) AR022510A1 (https=)
AT (1) ATE413188T1 (https=)
AU (1) AU764138B2 (https=)
CA (1) CA2361837C (https=)
CY (1) CY1108702T1 (https=)
DE (1) DE60040727D1 (https=)
DK (1) DK1150712T3 (https=)
ES (1) ES2313881T3 (https=)
PT (1) PT1150712E (https=)
SI (1) SI1150712T1 (https=)
WO (1) WO2000045841A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982950B (en) * 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2420247A1 (en) * 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
CA2327950A1 (en) * 2000-12-08 2002-06-08 Groupe Minutia Inc. Grain refining agent for cast aluminum or magnesium products
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AR038153A1 (es) * 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
MXPA06007635A (es) 2003-12-30 2007-01-30 Wyeth Corp Formulaciones de proteinas hidrofobas en una composicion inmunogenica que tiene tolerabilidad mejorada.
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2006037787A2 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
BRPI0516476A (pt) * 2004-10-05 2008-09-02 Cytos Biotechnology Ag conjugados de antìgeno de vlp e seu uso como vacinas
JP4182074B2 (ja) * 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
AU2006220835B2 (en) 2005-03-04 2012-01-19 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
US20140127260A1 (en) * 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CA2841356C (en) * 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
WO2013106398A1 (en) 2012-01-09 2013-07-18 Sanofi Pasteur Biologics, Llc Purification of herpes virus
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
EP2865390B1 (en) 2012-06-20 2019-08-21 The University of Tokyo Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
SI2939025T1 (sl) * 2012-12-28 2018-09-28 Cellestis Limited Preizkus celično posredovanega imunskega odziva
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
CN104479892A (zh) * 2014-11-06 2015-04-01 王越 一种具有植物杀菌功能洗衣液的制备方法
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4483903A3 (en) * 2016-04-01 2025-04-02 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
US12508279B2 (en) 2016-04-01 2025-12-30 Colorado State University Research Foundation Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
MX2020004434A (es) * 2017-11-01 2020-08-06 Merck Sharp & Dohme Formulaciones estables de citomegalovirus.
CN112439059B (zh) * 2019-09-02 2022-02-08 怡道生物科技(苏州)有限公司 重组人乳头瘤病毒疫苗组合物及其用途
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2026000483A (ja) * 2022-11-22 2026-01-06 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン
WO2025216920A1 (en) * 2024-04-08 2025-10-16 The Government Of The United States, As Represented By The Secretary Of The Army Freezable aqueous aluminum salt adjuvants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
JP3863559B2 (ja) * 1994-05-16 2006-12-27 メルク エンド カンパニー インコーポレーテッド 乳頭腫ウィルスワクチン
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EP0939648B1 (en) * 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
JP4598201B2 (ja) * 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤

Also Published As

Publication number Publication date
JP2002536340A (ja) 2002-10-29
KR20010093290A (ko) 2001-10-27
AU2749200A (en) 2000-08-25
US6251678B1 (en) 2001-06-26
JP2011225578A (ja) 2011-11-10
ES2313881T3 (es) 2009-03-16
DK1150712T3 (da) 2009-02-02
PT1150712E (pt) 2008-12-22
CA2361837A1 (en) 2000-08-10
ATE413188T1 (de) 2008-11-15
DE60040727D1 (de) 2008-12-18
EP1150712A2 (en) 2001-11-07
AU764138B2 (en) 2003-08-14
SI1150712T1 (sl) 2009-02-28
EP1150712B1 (en) 2008-11-05
CY1108702T1 (el) 2013-09-04
WO2000045841A3 (en) 2000-12-14
JP4841726B2 (ja) 2011-12-21
CA2361837C (en) 2011-06-07
WO2000045841A2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
AR022510A1 (es) Formulaciones de vacunas contra el papilomavirus humano
CY1116491T1 (el) Εμβολιο εναντι του αφθωδους πυρετου
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
CY1107457T1 (el) Εμβoλιο κατa του hpv
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
ECSP045300A (es) Antígenos virales
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
WO2001068129A3 (de) Adjuvans für vakzinen
PE20001338A1 (es) Uso de interleuquina 10 para el tratamiento de infecciones causadas por el virus de la hepatitis c
CA2331368A1 (en) Nucleic acid vaccines for prevention of flavivirus infection
NO994879L (no) Stabiliserte humane papillomvirusformuleringer
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
EP1223976A4 (en) A NEW METHOD FOR THE PRODUCTION OF VIRUS-LIKE PARTICLES OF HUMAN PAPILLOMA VIRUS WITH IMPROVED PROPERTIES
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
RU2006118106A (ru) Вектор химерного аденовируса типа 5/типа 35